SCHEMBL2530071

SCHEMBL2530071

O=C(c1ccccc1)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.74
HTT P42858 3/20 0.74
CCR9 P51686 7/20 0.61
MAPT P10636 3/20 0.60
TP53 P04637 1/20 0.60
KMT2A Q03164 1/20 0.60
CCR2 P41597 2/20 0.58
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
CCR4 P51679 1/20 0.58
CCR5 P51681 1/20 0.58
KCNH2 Q12809 1/20 0.58
ACLY P53396 2/20 0.56
SLC10A6 Q3KNW5 1/20 0.55
ALDH1A1 P00352 2/20 0.54
KCNA5 P22460 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13146558 0.91 LMNA (0.71) LMNAHTTCCR9MAPTTP53
SCHEMBL28006 0.90 LMNA (0.86) LMNAHTTCCR9MAPTTP53
SCHEMBL13146603 0.90 LMNA (0.77) LMNAHTTCCR9MAPTTP53
SCHEMBL13146484 0.89 LMNA (0.60) LMNAHTTCCR9MAPTTP53
SCHEMBL3083603 0.89 LMNA (0.75) LMNAHTTCCR9MAPTTP53
SCHEMBL3088122 0.89 KMT2A (0.62) LMNAHTTKMT2ACCR2CYP1A2
SCHEMBL27979 0.89 LMNA (0.83) LMNAHTTCCR9MAPTTP53
SCHEMBL2532380 0.88 LMNA (0.71) LMNAHTTCCR9MAPTTP53
SCHEMBL13146602 0.87 SLC25A1 (0.69) LMNAHTTCCR9MAPTTP53
SCHEMBL13146487 0.87 LMNA (0.66) LMNAHTTCCR9MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008008374-A2 CCR2 INHIBITORS AND METHODS OF USE THEREOF CHEMOCENTRYX, INC. (US) 2008-01-17 WO claimed
US-8642808-B2 Bis-aryl sulfonamides CHEMOCENTRYX, INC. (US) 2014-02-04 US disclosed
US-20110257183-A1 BIS-ARYL SULFONAMIDES UNGASHE SOLOMON 2011-10-20 US disclosed
US-20110257183-A1 BIS-ARYL SULFONAMIDES UNGASHE SOLOMON 2011-10-20 US disclosed
US-20110257183-A1 BIS-ARYL SULFONAMIDES UNGASHE SOLOMON 2011-10-20 US disclosed
US-20100234364-A1 CCR2 INHIBITORS AND METHODS OF USE THEREOF CHEMOCENTRYX, INC. 2010-09-16 US disclosed
US-20100234364-A1 CCR2 INHIBITORS AND METHODS OF USE THEREOF CHEMOCENTRYX, INC. 2010-09-16 US disclosed
US-20100234364-A1 CCR2 INHIBITORS AND METHODS OF USE THEREOF CHEMOCENTRYX, INC. 2010-09-16 US disclosed
US-20100227902-A1 BIS-ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2010-09-09 US disclosed
US-20100227902-A1 BIS-ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2010-09-09 US disclosed
US-20070203131-A1 Bis-aryl sulfonamides CHEMOCENTRYX, INC. 2007-08-30 US disclosed
US-20070203131-A1 Bis-aryl sulfonamides CHEMOCENTRYX, INC. 2007-08-30 US disclosed
US-7227035-B2 Bis-aryl sulfonamides CHEMOCENTRYX (US) 2007-06-05 US disclosed
US-7227035-B2 Bis-aryl sulfonamides CHEMOCENTRYX (US) 2007-06-05 US disclosed
US-7227035-B2 Bis-aryl sulfonamides CHEMOCENTRYX (US) 2007-06-05 US disclosed
WO-2005112916-A2 BIS-ARYL SULFONAMIDES CHEMOCENTRYX, INC. (US) 2005-12-01 WO disclosed
EP-1567486-A2 BIS-ARYL SULFONAMIDES Chemocentryx (US) 2005-08-31 EP disclosed
US-20050137179-A1 Bis-aryl sulfonamides CHEMOCENTRYX, INC. 2005-06-23 US disclosed
WO-2004085384-A2 BIS-ARYL SULFONAMIDES CHEMOCENTRYX (US) 2004-10-07 WO disclosed
US-20040167113-A1 Bis-aryl sulfonamides CHEMOCENTRYX, INC. 2004-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227902-A1 BIS-ARYL SULFONAMIDES CCR2, CXCR2, CCL2 LMNA 4769/4885HTT 3567/4885CCR9 14/4885
US-20050137179-A1 Bis-aryl sulfonamides CCR2, CXCR2, CCL2 LMNA 4769/4885HTT 3567/4885CCR9 14/4885
US-20070203131-A1 Bis-aryl sulfonamides CCR2, CXCR2, CCL2 LMNA 4769/4885HTT 3567/4885CCR9 14/4885
US-20100234364-A1 CCR2 INHIBITORS AND METHODS OF USE THEREOF CCR2, CCR9, CCR1 LMNA 4007/4885HTT 3097/4885CCR9 2/4885
US-20040167113-A1 Bis-aryl sulfonamides CCR2, CXCR2, CCL2 LMNA 4769/4885HTT 3567/4885CCR9 14/4885
US-20110257183-A1 BIS-ARYL SULFONAMIDES CCR2, CXCR2, CCL2 LMNA 4769/4885HTT 3567/4885CCR9 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.